Quantitative detection method of daclatasvir in beagle plasma

Abstract

The invention discloses a quantitative detection method of daclatasvir in beagle plasma, and belongs to the technical field of drug detection. The quantitative detection method comprises the followingsteps of: 1) preparing a daclatasvir series working solution and a daclatasvir-d6 internal standard working solution; 2) pretreating to-be-detected beagle plasma; 3) preparing a series of calibrationstandard samples and accompanying quality control samples; and (4) measuring the concentration of the daclatasvir in the to-be-measured beagle plasma, wherein a standard curve is drawn by taking a chromatographic peak area ratio of the daclatasvir to the internal standard daclatasvir-d6 as a vertical coordinate and taking the concentration of the daclatasvir in the beagle blank plasma as a horizontal coordinate, and the concentration of the daclatasvir in the to-be-measured beagle plasma is calculated according to the standard curve. According to the quantitative detection method, a protein precipitation method is adopted to treat a beagle plasma sample, an electrospray ion source is used as an ionization technology, the detection method is simple and convenient to operate, high in sensitivity, good in reproducibility, high in selectivity, low in detection limit, short in analysis time and suitable for high-throughput quantitative determination of the beagle plasma sample and preclinical beagle in-vivo pharmacokinetic research.

Description

Technical field[0001]The invention relates to a detection of drug concentration, belonging to the technical field of drug detection, and in particular to a quantitative detection method of dalatavir in the plasma of beagle dogs.Background technique[0002]Hepatitis C is one of the common clinical infectious diseases. Hepatitis C has been recognized as the main cause of chronic liver disease worldwide. About 27% of liver cirrhosis and 25% of hepatocellular carcinoma are caused by hepatitis C. Hepatitis C has become a public health problem that cannot be ignored and has attracted widespread attention from the whole society.[0003]Dalatavir is a selective HCV non-structural protein 5a replica inhibitor, highly specific to multiple chronic hepatitis C (HCV) genotypes / subtypes, and low toxicity to host cells. It was developed by Bristol-Myers Squibb and was approved for marketing by the European Union at the end of 2014, combined with other drugs for the treatment of adults with chronic hep...

AI Technical Summary

Problems solved by technology

However, the prior art does not disclose its drug detection method in animals, so it is necessary to develop a fast, sensitive and accurate analytical method to quantify the concentration of daclatasvir in plasma

Images